Trade Idea: Trump imposes tariff on pharmaceuticals before May?
Market: Trump imposes tariff on pharmaceuticals before May?
Trade: No
Current Odds: 80%
Return: 25%
Resolved by: End of April (2 weeks)
Position Size: Full
Hey all and welcome back to the Poly. In case you missed it, we launched our Polymarket account three weeks ago, and have returned 15% on the whole account - solely based on the trades and position sizes we talk about on this newsletter. This puts us on track for a 535% yearly gain. If you would like to follow our progress check out the account here.
Today’s trade is based on the Trump administration's latest moves on trade that have sparked fresh debates about possible tariffs on pharmaceuticals. Pharma is a sector that matters deeply for both public health and the economy, which meant it was somewhat of a relief when pharmaceutical products weren't included when the administration unveiled wide-ranging tariffs on imports from more than 180 countries on April 2nd. Later, on April 15, the administration launched a national security investigation into drug imports under Section 232. This sequence of events highlights just how complicated and delicate any decisions about this industry really are.
Procedural Hurdles and the Section 232 Investigation Timeline
On April 15, the Commerce Department kicked off a Section 232 investigation into pharmaceutical imports, positioning foreign drug production as a national security issue. The Trade Expansion Act of 1962 requires these investigations to follow a specific timeline: the Commerce Secretary gets 270 days to deliver findings to the President, who then has 90 days to take action.
While Trump's team has moved quickly on similar investigations before (like with steel and aluminum), this pharmaceutical probe is particularly complex. It covers a wide range of products; everything from brand-name and generic drugs to active ingredients and manufacturing equipment, which makes a fast resolution much harder. The investigation's public comment period runs for 21 days, which pushes the process into mid-May at minimum. Even if the administration tries to rush things, the legal groundwork needed to justify tariffs on national security grounds makes any April implementation practically impossible.
Historical examples make April action even less likely. When the Trump administration imposed Section 232 tariffs on steel and aluminum in 2018, those came a full 14 months after investigations started. Meanwhile, the auto sector investigation that began in May 2018 still hasn't been resolved, even now in April 2025. With the pharmaceutical investigation only starting on April 15, there's simply not enough time for officials to gather data, talk with industry stakeholders, and create a legally sound justification before the end of the month.
Political Sensitivity of Targeting Healthcare Costs
The U.S. healthcare system is already struggling with sky-high drug prices, which became a major talking point in congressional hearings and throughout the 2024 presidential race. Putting tariffs on pharmaceuticals would directly clash with the Trump administration's promises to lower costs for Americans.
As Melissa Barber from Yale University points out, brand-name drugs are already "priced at the maximum the market can sustain," leaving manufacturers little choice but to pass any new costs directly to consumers. Generic drugs make up 90% of U.S. prescriptions, but their razor-thin profit margins (just 3-5% on average) mean that tariff-related price increases would be unavoidable.
Robin Feldman of UC San Francisco cautions that even small cost increases could limit access to essential medications, potentially triggering significant political backlash.
Pharmaceutical industry groups like PhRMA and the Biotechnology Innovation Organization are pushing back hard against the tariffs, warning they could disrupt supply chains and hamper innovation. A recent BIO survey revealed that 90% of U.S. biotech companies depend on imported components, and half of them expect regulatory delays and R&D reductions if tariffs move forward. This resistance adds to the political challenges facing an administration already under fire for healthcare costs.
Strategic Timing and the April 2 Tariff Exclusion
The administration's choice to leave pharmaceuticals out of both the April 2 baseline 10% tariffs and the April 9 reciprocal tariffs aimed at "worst offenders" signals a careful approach. This stands in stark contrast to semiconductors, which got hit with immediate tariffs despite also being under Section 232 investigations. The difference highlights pharmaceuticals' unique position: unlike when electronics are in short supply, drug shortages can literally mean life or death, making the political risks of a misstep much higher.
President Trump's April 9th announcement of a 90-day tariff pause for most countries shows he prefers negotiation over sudden action. This breathing room lets his administration seek concessions from key generic drug suppliers like Ireland and India without causing immediate price increases. By holding off on pharmaceutical tariffs, Trump keeps valuable bargaining chips for future trade deals while avoiding short-term disruptions to healthcare.
Economic Realities of Pharmaceutical Manufacturing
The Trump administration's push to bring drug manufacturing back to America faces huge short-term challenges. As Lilly CEO Dave Ricks pointed out, moving production from places like Ireland and India would take "years and billions of dollars." The complicated regulatory approvals needed for manufacturing facilities, plus the specialized workforce and infrastructure required, make quick reshoring impossible. Any tariffs imposed in April would just punish imports without actually boosting U.S. production, defeating their supposed purpose.
The pharmaceutical industry's global supply chains make tariff implementation even more complicated. A full 80% of active pharmaceutical ingredients used in U.S. drugs come from overseas, mainly from China and India. Disrupting these networks with tariffs would send shockwaves through the entire healthcare system, affecting everything from antibiotics to cancer treatments. Novartis recently announced a $23 billion investment plan for the U.S. just days before the Section 232 investigation was launched – a clear attempt to head off tariffs – but even these initiatives will take five years to fully develop.
The combination of procedural delays, political risks, economic challenges, and strategic timing makes pharmaceutical tariffs in April 2025 extremely unlikely. By focusing on sectors that can be reshored more quickly, like semiconductors, and have lower public sensitivity, the administration is clearly trying to avoid healthcare-related backlash. Looking ahead, expect drawn-out negotiations and gradual policy changes rather than sudden tariff announcements. That said, the Section 232 investigation does set the stage for possible future actions, especially if the administration can secure concessions from other countries or develop better domestic production incentives. For now, the delicate balance between trade policy goals and healthcare realities is keeping pharmaceuticals safe from immediate tariff shocks.
Thank you for reading The Poly, the #1 newsletter for prediction markets.
If you enjoyed this analysis, please help us by clicking the “♡ Like” button.
Risk warning and disclaimer: The Poly Newsletter is for information and entertainment purposes only and should not be regarded as investment advice. Betting on prediction markets is high risk and can result in significant financial loss. Professional bettors typically risk no more than 0.5-2% of their capital on any one trade. No warranty is made to the accuracy, completeness or correctness of the information provided. The information in the publication may become outdated and there is no obligation to update any such information. Never bet more than you can afford to lose.